A Phase I/III Clinical Study of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear

Phase 3

Completed

• Conditions: Rotator Cuff Injuries
• Interventions: Procedure: Arthroscopic surgery; Biological: TPX-114

• Registration Number: NCT03668028
• Lead Sponsor: Tego Science, Inc.

Brief Summary

Rotator cuff tear is one of the most common shoulder diseases and retears occur frequently after arthroscopic repair. Therefore, there is a growing need of new therapy to improve structural outcome. This study evaluates the efficacy and safety of autologous fibroblasts during arthroscopic repair. The primary outcome is the retear rate at 24 weeks after administration of autologous fibroblasts (TPX-114) during arthroscopic repair. Secondary outcomes are functional evaluations including Range of Motion (ROM), Constant Score (CS), American Shoulder and Elbow Surgeons (ASES) score and Simple Shoulder Test (SST) at 24 and 52 weeks after administration.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-07-09
• Study First Submitted: 2018-09-11
• Study First Submitted QC: 2018-09-11
• Study First Posted: 2018-09-12
• Primary Completion: 2021-09-27
• Study Completion: 2022-04-28
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-17
• Last Update Posted: 2023-05-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 93

Inclusion Criteria

Participants must;

1. Be 19 years of age or older.
2. Require arthroscopic repair for full-thickness rotator cuff tear(>2cm, ≤5cm) assessed by MRI without improvement of symptoms despite more than 3 months of conservative management.
3. Consent to undergo skin biopsy to manufacture test product.
4. Understand fully the study and voluntarily sign the informed consent for participation in the study.

Exclusion Criteria

Participants with any of the following conditions will be excluded unless stated otherwise;

1. Unsuitable for skin biopsy.

2. Have additional subscapularis tear.

3. Have prior medical history of the following at the time of screening.

   • Operation of the affected shoulder
   • Allergies to bovine proteins
   • Anaphylaxis to gentamicin
   • Coagulopathy
   • Genetic disorders affecting fibroblasts or collagen (ex. achondroplasia, osteogenesis imperfecta)
   • Malignant tumors within the last 5 years

4. Have been diagnosed with any of the following diseases at the time of screening.

   • Autoimmune disease (including RA)
   • HIV Ab-positive
   • Acute trauma, chronic shoulder dislocation, pyogenic infection on the affected shoulder
   • Scapulohumeral osteoarthritis

5. Be pregnant, breastfeeding, planning pregnancy or unwilling to use of contraceptives suggested in this study.

6. Other surgical or nonsurgical procedures on the affected shoulder to be judged more appropriate than arthroscopic repair.

7. Have participated in and received investigational agents in other clinical trials within 4 weeks of this study.

8. Be deemed inadequate for the study by investigators.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Arthroscopic surgery	Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.
TPX-114	Arthroscopic surgery	Subjects undergo arthroscopic rotator cuff repair with TPX-114.
TPX-114	TPX-114	Subjects undergo arthroscopic rotator cuff repair with TPX-114.

Primary Outcome Measures

Name	Time	Method
Retear Rate	24 weeks	Retear rate assessed by an independent evaluator with MRI

Trial Locations

Locations (2)

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Gyeonggi-do, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of